Literature DB >> 27659489

Commentary on tumor heterogeneity.

Helmut H Popper1.   

Abstract

Entities:  

Year:  2016        PMID： 27659489      PMCID： PMC5009086          DOI： 10.21037/tlcr.2016.08.07

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  18 in total

1.  Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer.

Authors:  Michio Inukai; Shinichi Toyooka; Sachio Ito; Hiroaki Asano; Shuji Ichihara; Junichi Soh; Hiroshi Suehisa; Mamoru Ouchida; Keisuke Aoe; Motoi Aoe; Katsuyuki Kiura; Nobuyoshi Shimizu; Hiroshi Date
Journal:  Cancer Res       Date:  2006-08-15       Impact factor: 12.701

2.  Rebuttal from Dr. Hofman and Dr. Ilié.

Authors:  Marius Ilié; Paul Hofman
Journal:  Transl Lung Cancer Res       Date:  2016-08

3.  Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma.

Authors:  Katerina Politi; Pang-Dian Fan; Ronglai Shen; Maureen Zakowski; Harold Varmus
Journal:  Dis Model Mech       Date:  2009-12-09       Impact factor: 5.758

4.  Assessment of intratumoral heterogeneity of oncogenic driver mutations in surgically-resected lung adenocarcinoma: implications of percutaneous biopsy-based molecular assay for target-directed therapy.

Authors:  Hong Kwan Kim; Ho Yun Lee; Yoon-La Choi; So-Jung Choi; Haejoo Choi; Jinseon Lee; Joungho Han; Myung-Ju Ahn; Kyung Soo Lee; Jhingook Kim
Journal:  Anticancer Res       Date:  2014-02       Impact factor: 2.480

5.  Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma.

Authors:  Weijing Cai; Dongmei Lin; Chunyan Wu; Xuefei Li; Chao Zhao; Limou Zheng; Shannon Chuai; Ke Fei; Caicun Zhou; Fred R Hirsch
Journal:  J Clin Oncol       Date:  2015-09-28       Impact factor: 44.544

6.  Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer.

Authors:  Sarah Park; Alison J Holmes-Tisch; Eun Yoon Cho; Young Mog Shim; Jinkook Kim; Hyo Song Kim; Jeeyun Lee; Yeon Hee Park; Jin Seok Ahn; Keunchil Park; Pasi A Jänne; Myung-Ju Ahn
Journal:  J Thorac Oncol       Date:  2009-07       Impact factor: 15.609

7.  Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing.

Authors:  Jianjun Zhang; Junya Fujimoto; Jianhua Zhang; David C Wedge; Xingzhi Song; Jiexin Zhang; Sahil Seth; Chi-Wan Chow; Yu Cao; Curtis Gumbs; Kathryn A Gold; Neda Kalhor; Latasha Little; Harshad Mahadeshwar; Cesar Moran; Alexei Protopopov; Huandong Sun; Jiabin Tang; Xifeng Wu; Yuanqing Ye; William N William; J Jack Lee; John V Heymach; Waun Ki Hong; Stephen Swisher; Ignacio I Wistuba; P Andrew Futreal
Journal:  Science       Date:  2014-10-10       Impact factor: 47.728

Review 8.  Progression and metastasis of lung cancer.

Authors:  Helmut H Popper
Journal:  Cancer Metastasis Rev       Date:  2016-03       Impact factor: 9.264

9.  Molecular profiling of lung adenosquamous carcinoma: hybrid or genuine type?

Authors:  Erik Vassella; Stephanie Langsch; Matthias S Dettmer; Cornelia Schlup; Maja Neuenschwander; Milo Frattini; Mathias Gugger; Stephan C Schäfer
Journal:  Oncotarget       Date:  2015-09-15

Review 10.  Mutation status concordance between primary lesions and metastatic sites of advanced non-small-cell lung cancer and the impact of mutation testing methodologies: a literature review.

Authors:  James Sherwood; Simon Dearden; Marianne Ratcliffe; Jill Walker
Journal:  J Exp Clin Cancer Res       Date:  2015-09-04
View more
  7 in total

Review 1.  Liquid biopsies come of age: towards implementation of circulating tumour DNA.

Authors:  Jonathan C M Wan; Charles Massie; Javier Garcia-Corbacho; Florent Mouliere; James D Brenton; Carlos Caldas; Simon Pacey; Richard Baird; Nitzan Rosenfeld
Journal:  Nat Rev Cancer       Date:  2017-02-24       Impact factor: 60.716

2.  Genomic Alteration Spectrum of Non-Small Cell Lung Cancer Patients in East-China Characterized by Tumor Tissue DNA and Cell-Free DNA.

Authors:  Jie Li; Siwen Chen; Hui Xue; Haoyi Wang; Tianwei Huang; Hongya Xie; Jiang He; Cai Ke; Zhaonan Yu; Bin Ni
Journal:  Onco Targets Ther       Date:  2022-05-19       Impact factor: 4.345

Review 3.  Clinical utility of circulating tumor DNA for colorectal cancer.

Authors:  Hiroki Osumi; Eiji Shinozaki; Kensei Yamaguchi; Hitoshi Zembutsu
Journal:  Cancer Sci       Date:  2019-03-04       Impact factor: 6.716

Review 4.  Prediction of the treatment response in ovarian cancer: a ctDNA approach.

Authors:  Mina Sharbatoghli; Somayeh Vafaei; Hamidreza Aboulkheyr Es; Mohsen Asadi-Lari; Mehdi Totonchi; Zahra Madjd
Journal:  J Ovarian Res       Date:  2020-10-19       Impact factor: 4.234

Review 5.  Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices.

Authors:  Midhun Malla; Jonathan M Loree; Pashtoon Murtaza Kasi; Aparna Raj Parikh
Journal:  J Clin Oncol       Date:  2022-07-15       Impact factor: 50.717

Review 6.  Liquid biopsy for the assessment of adrenal cancer heterogeneity: where do we stand?

Authors:  Pál Perge; Gábor Nyirő; Bálint Vékony; Peter Igaz
Journal:  Endocrine       Date:  2022-05-13       Impact factor: 3.925

7.  Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection.

Authors:  Clare Fiala; Eleftherios P Diamandis
Journal:  BMC Med       Date:  2018-10-02       Impact factor: 8.775
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.